What is pleuropulmonary blastoma?
Pleuropulmonary blastoma (PPB) is a rare cancer of the lung or the lining of the chest (pleura) that affects babies and young children. It is the most common primary lung cancer of early childhood, although it is still very rare.
PPB develops from immature, embryo-like tissue in the lung. It often starts as one or more air-filled cysts. Over time, some cysts can change into solid, fast-growing tumours.
Doctors describe PPB in three main types, which reflect how far it has progressed. Early detection of the cystic form greatly improves the outlook (Messinger et al., 2015).
Most children with PPB carry a change in the DICER1 gene. This means many cases are linked with an inherited tumour predisposition, called DICER1 syndrome (Hill et al., 2009). Families are therefore offered genetic counselling and testing.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Embryonal sarcoma-like tumour of the lung or pleura |
| How common | Very rare; a few dozen children are diagnosed each year in the US |
| Typical age | Almost always under 6; most under 3 |
| Types | Type I (cystic), Type Ir (regressed), Type II (cystic and solid), Type III (solid) |
| Genetic link | Germline DICER1 variant in about two-thirds or more of children |
| Main treatment | Surgery; chemotherapy for most Type II and III tumours |
| Outlook | Excellent for Type I; poorer for Types II and III |
2. Types of pleuropulmonary blastoma
The type of PPB is the most important factor in planning treatment (Priest et al., 1997; Messinger et al., 2015):
| Type | Appearance | Usual age at diagnosis | 5-year survival (approx.) |
|---|---|---|---|
| Type I | Purely cystic, with thin walls and a layer of immature cells | About 8 months | Over 90% |
| Type Ir | Cystic, without immature cells (“regressed”) | Any age, including adults | Close to 100% |
| Type II | Cysts with solid areas | About 3 years | About 70% |
| Type III | Completely solid | About 3-4 years | About 50-55% |
Type I PPB can progress to Type II or III if it is not removed. This progression usually happens in the first few years of life, which is why early detection matters so much.
3. Causes and risk factors
DICER1 gene
The DICER1 gene helps cells make tiny RNA molecules (microRNAs). These molecules control how other genes work during development.
In PPB, the tumour cells usually have two changes in DICER1. One is often inherited (germline), and the second arises in the lung tissue (Hill et al., 2009).
DICER1 syndrome
People with a germline DICER1 variant have a higher risk of certain tumours, although most carriers never develop cancer (Schultz et al., 2018):
| Associated condition | Notes |
|---|---|
| Pleuropulmonary blastoma | Mostly before age 6 |
| Cystic nephroma | Kidney cysts, usually benign |
| Sertoli-Leydig cell tumour | Ovarian tumour in girls and young women |
| Multinodular goitre and thyroid cancer | Thyroid lumps in children and adults |
| Embryonal rhabdomyosarcoma of the cervix | In girls and young women |
| Ciliary body medulloepithelioma | Eye tumour |
| Nasal chondromesenchymal hamartoma | Nose tumour |
| Pineoblastoma and pituitary blastoma | Rare brain tumours |
PPB is not caused by anything the parents did during pregnancy, and it is not infectious.
4. How does it look
On scans
| Type | Chest X-ray and CT appearance |
|---|---|
| Type I | One or more air-filled cysts in the lung, sometimes with a collapsed lung (pneumothorax) |
| Type II | Cysts with solid nodules or thickened walls |
| Type III | A large solid mass filling much of one side of the chest, often pushing the heart and windpipe to the other side |
Type I PPB can look very similar to a benign lung malformation called congenital pulmonary airway malformation (CPAM). Features such as multiple cysts, cysts in both lungs, pneumothorax or a family history of DICER1-related tumours raise suspicion of PPB.
The tumour itself
| Type | What the surgeon or pathologist sees |
|---|---|
| Type I | Thin-walled cysts lined by normal-looking cells, with small immature cells beneath |
| Type II | Cysts with grey-white, fleshy solid areas |
| Type III | Soft, solid tumour with areas of bleeding, dead tissue and sometimes cartilage |
Under the microscope, Types II and III contain primitive blastema cells, areas resembling rhabdomyosarcoma and immature cartilage. Some show anaplasia, very large abnormal nuclei, which is linked with a poorer outlook.
Visible signs in the child
| Sign | What it looks like |
|---|---|
| Fast or laboured breathing | Chest drawing in with each breath, flaring nostrils |
| Blue tinge to lips or skin | From low oxygen, especially with pneumothorax |
| Uneven chest movement | One side moves less |
| Tiredness and poor feeding | In babies and toddlers |
5. Symptoms
Symptoms depend on the type and size of the tumour. Type I PPB may cause no symptoms and be found by chance, or during screening of a child known to carry a DICER1 variant.
Common symptoms
- Breathing difficulty or fast breathing
- Cough, sometimes persistent
- Fever and repeated chest infections, which may be mistaken for pneumonia
- Chest or abdominal pain
- Sudden breathlessness from a collapsed lung (pneumothorax), especially in Type I
- Tiredness, poor appetite and weight loss
- Poor feeding in babies
Symptoms of spread
Types II and III can spread, most often to the brain and bones:
- Headaches, vomiting, unsteadiness or seizures if the brain is involved
- Bone pain or limping if bones are involved
When to seek medical advice
Seek urgent medical help if a child has sudden difficulty breathing, blue lips or severe chest pain.
See a doctor if a child has a cough or chest infections that keep coming back, or unexplained tiredness and weight loss.
6. Diagnosis
| Test | Purpose |
|---|---|
| Chest X-ray | Often the first test; shows cysts, a mass or pneumothorax |
| CT scan of the chest | Shows the size, type and position of the tumour |
| Surgery or biopsy | Confirms the diagnosis and type |
| MRI of the brain | Checks for spread, especially in Types II and III |
| Bone scan or PET-CT | Checks for spread to bones in solid types |
| DICER1 testing | Blood test for an inherited variant; tumour testing also helps confirm diagnosis |
| Kidney ultrasound | Looks for cystic nephroma in DICER1 carriers |
Specialist pathology review is important, because PPB is rare and Type I tumours can be mistaken for benign cysts. Doctors also check carefully for other DICER1-related conditions at the time of diagnosis. The International PPB/DICER1 Registry offers central review and advice to families and doctors.
7. Treatment
PPB is treated by a children’s cancer team at a specialist centre. Treatment plans follow international recommendations (Bisogno et al., 2021).
Surgery
Complete surgical removal of the tumour is the main treatment for every type.
| Type | Surgery |
|---|---|
| Type I and Ir | Removal of the cystic area, often a lobe of the lung; may be all that is needed |
| Type II and III | Surgery at diagnosis if safe, or after chemotherapy has shrunk the tumour |
Chemotherapy
| Type | Chemotherapy |
|---|---|
| Type I | Sometimes given if the tumour could not be removed completely or has a higher risk of progression |
| Type Ir | Not needed |
| Type II and III | Recommended for almost all children, using sarcoma-type regimens |
Common regimens include IVADo (ifosfamide, vincristine, actinomycin D, doxorubicin) and VAC (vincristine, actinomycin D, cyclophosphamide). Treatment usually lasts several months. Doxorubicin-containing regimens appear to give the best results for Types II and III (Schultz et al., 2023).
Radiotherapy
Radiotherapy is used selectively, for example when tumour remains after surgery or when there is spread to the brain.
Side effects
| Side effect | Support |
|---|---|
| Low blood counts and infections | Regular blood tests; urgent treatment for fever |
| Sickness and poor appetite | Anti-sickness medicines and nutritional support |
| Hair loss | Temporary |
| Heart effects | From doxorubicin; heart scans are done during and after treatment |
| Kidney and hearing effects | Monitored during and after treatment |
8. Outlook (prognosis)
The outlook depends mainly on the type of PPB:
| Factor | Effect |
|---|---|
| Type I or Ir | Excellent; most children are cured with surgery |
| Type II | About 70% survive long term |
| Type III | About half survive long term |
| Complete removal of the tumour | Better outlook |
| Spread to brain or bone | Poorer outlook |
| Anaplasia | Linked with poorer outcomes |
Relapse usually happens within the first 2-3 years after treatment. Long-term follow-up therefore includes regular chest scans and brain imaging for children with solid types.
9. Screening children with DICER1 variants
Because Type I PPB is highly curable, children known to carry a germline DICER1 variant are offered surveillance. This allows any lung cysts to be found early (Schultz et al., 2018).
| Age | Typical surveillance |
|---|---|
| Birth to about 6 years | Chest X-ray every few months and a chest CT scan in early infancy and again in early childhood |
| Up to about 12 years | Less frequent chest X-rays |
| Childhood onwards | Kidney ultrasound, thyroid ultrasound and, for girls, pelvic ultrasound at set intervals |
Exact schedules vary between countries, and families agree on a plan with their genetics team.
Why screening matters
A small, purely cystic Type I tumour can usually be removed with a single operation, and most children need no chemotherapy. A solid Type III tumour, in contrast, needs months of intensive treatment and has a much poorer outlook.
Finding cysts early, before they change, is therefore the main way to improve results for children who carry a DICER1 variant. Scans are timed to cover the years when the risk of PPB is highest.
Parents who carry a DICER1 variant themselves may also be offered thyroid checks and, for women, pelvic ultrasound, since DICER1-related tumours can appear in adults too.
10. Long-term effects and follow-up
Most children treated for Type I PPB grow up with normal lung function, even after part of a lung has been removed. The remaining lung grows and adapts well in young children.
Children treated with chemotherapy and radiotherapy need longer follow-up for late effects:
| Possible late effect | Notes |
|---|---|
| Heart function | Checked with heart scans after doxorubicin |
| Kidney function | Ifosfamide can affect the kidneys |
| Hearing | Checked if platinum drugs were given |
| Growth and fertility | Reviewed through childhood and adolescence |
| Chest wall and spine | Surgery or radiotherapy can affect chest growth; physiotherapy helps |
| Second tumours | DICER1 carriers need lifelong awareness of related tumours |
Follow-up usually moves to a late-effects clinic once treatment has finished for several years.
11. Living with PPB
- Keep follow-up appointments for scans and blood tests
- Know the signs of a collapsed lung and seek urgent help if they appear
- Avoid smoke exposure, and keep vaccinations up to date
- Ask about late effects, including heart, kidney, hearing and fertility checks
- Seek support from children’s cancer charities and family support services
- Talk to the school about time off, infection risk and help with catching up
- Look after brothers and sisters, who may also need support and explanation
12. Frequently asked questions
| Question | Answer |
|---|---|
| Is PPB the same as lung cancer in adults? | No. It is a completely different childhood tumour |
| Is it inherited? | Often. Most children carry a DICER1 variant, which may have come from a parent |
| Should brothers and sisters be tested? | Yes, genetic testing is usually offered to the family |
| Can a lung cyst become cancer? | In DICER1 carriers, some cysts are Type I PPB and can progress, which is why they are removed |
| Will my child have long-term problems? | Most children recover well, but some need follow-up for late effects of chemotherapy or surgery |
13. Questions to ask your care team
- What type of PPB does my child have?
- Can the tumour be completely removed?
- Will my child need chemotherapy or radiotherapy?
- Should we have DICER1 testing, and what does it mean for our family?
- What follow-up and screening will my child need?
- Which late effects should we watch for after treatment?
- Who can we contact out of hours if our child becomes unwell?
Resources
- Messinger, Y.H. et al. (2015) ‘Pleuropulmonary blastoma: a report on 350 central pathology-confirmed pleuropulmonary blastoma cases by the International Pleuropulmonary Blastoma Registry’, Cancer, 121(2), pp. 276-285.
- Priest, J.R. et al. (1997) ‘Pleuropulmonary blastoma: a clinicopathologic study of 50 cases’, Cancer, 80(1), pp. 147-161.
- Hill, D.A. et al. (2009) ‘DICER1 mutations in familial pleuropulmonary blastoma’, Science, 325(5943), p. 965.
- Schultz, K.A.P. et al. (2018) ‘DICER1 and associated conditions: identification of at-risk individuals and recommended surveillance strategies’, Clinical Cancer Research, 24(10), pp. 2251-2261.
- Bisogno, G. et al. (2021) ‘Pleuropulmonary blastoma in children and adolescents: the EXPeRT/PARTNER diagnostic and therapeutic recommendations’, Pediatric Blood and Cancer, 68(Suppl 4), p. e29045.
- Schultz, K.A.P. et al. (2023) ‘Outcomes for children with type II and type III pleuropulmonary blastoma following chemotherapy: a report from the International PPB/DICER1 Registry’, Journal of Clinical Oncology, 41(4), pp. 778-789.
- Dehner, L.P. et al. (2015) ‘Pleuropulmonary blastoma: evolution of an entity as an entry into a familial tumor predisposition syndrome’, Pediatric and Developmental Pathology, 18(6), pp. 504-511.
- National Cancer Institute (2026) Childhood Pleuropulmonary Blastoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/lung/hp/child-pleuropulmonary-blastoma-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.